Cagrilintide is a long-acting synthetic analogue of amylin (islet amyloid polypeptide, IAPP), a 37 amino acid peptide hormone co-secreted with insulin by pancreatic beta cells in response to nutrient intake. Cagrilintide was developed with structural modifications to extend its half-life significantly beyond that of native amylin, enabling sustained receptor engagement in research and clinical models.
Amylin Receptor Signaling Research
Cagrilintide has been studied for its interactions with amylin receptors (AMY1, AMY2, AMY3) in the central nervous system, particularly in hypothalamic regions associated with energy homeostasis signaling. Research has examined its effects on neuropeptide Y and POMC expression in preclinical models.
Metabolic and Satiety Pathway Research
Clinical and preclinical research has examined cagrilintide's interactions with glucagon secretion pathways, postprandial glucose modulation, and gastric emptying rate in experimental settings. Studies have explored its additive interactions with GLP-1 receptor agonist signaling.
Combination Research Studies
Cagrilintide has been studied in combination with semaglutide in clinical research under the designation CagriSema, examining the additive effects of dual amylin and GLP-1 receptor engagement on metabolic markers.
• Enebo LB et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg. The Lancet, 397(10286), 1736–1748.
• Frias JP et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide with semaglutide 2.4 mg. The Lancet, 402(10403), 720–730.
